The Role of Gastroesophageal Reflux in Scleroderma Pulmonary Fibrosis

Sponsor
Royal Brompton & Harefield NHS Foundation Trust (Other)
Overall Status
Unknown status
CT.gov ID
NCT02136394
Collaborator
(none)
100
2
37.9
50
1.3

Study Details

Study Description

Brief Summary

Scarring of the lungs is common in patients with scleroderma and is one of the main causes of death. Patients with scleroderma very frequently have problems with their gullet (esophagus), the food pipe that leads into the stomach.

Normally, a small circular muscle at the base of the esophagus opens to allow food to pass into the stomach and closes to keep the digestive fluids from flowing back up into the gullet. In patients with scleroderma, the muscle may become weak and no longer close properly. Gastroesophageal reflux (GER) is the medical term for reflux of stomach contents into the esophagus.

Our hypothesis is that small amounts of GER can move back up into the esophagus and get inhaled into the lungs, and may be one of the triggers for lung scarring. We propose to look for certain substances normally only found in the stomach in the "exhaled breath condensate" which is collected by breathing comfortably into a cooled cylinder, allowing the breath to condensate. In a smaller group of patients, we also plan to perform a bronchoalveolar lavage, a more widely studied test in which a small amount of fluid is introduced into a small part of the lungs through a fine tube, and then removed for examination, to evaluate whether the two tests provide similar measurements. We will also evaluate the correlation between these molecules and other tests, including lung function, and markers of lung scarring activity, and tests to look at how the esophagus is working so that we can get a clearer picture of how this affects patients' daily lives. Finally, we will be following up patients over time with lung function to see whether evidence of GER into the lungs is linked with a greater likelihood of worsening of lung scarring in the future.

Condition or Disease Intervention/Treatment Phase
  • Other: Gastro-esophageal reflux

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Investigation Into the Role of Gastroesophageal Reflux in Pulmonary Fibrosis in Scleroderma
Study Start Date :
Feb 1, 2014
Anticipated Primary Completion Date :
Dec 1, 2016
Anticipated Study Completion Date :
Apr 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Severe/moderate acid reflux

Other: Gastro-esophageal reflux
This is an observational study. The exposure is the gastro-esophageal reflux.

Mild/absent acid reflux

Outcome Measures

Primary Outcome Measures

  1. Measurements of pepsin and pH in the Exhaled breath condensate (EBC) [Baseline]

  2. In a subgroup pf 40 patients, measurements of pepsin and bile salts in bronchoalveolar lavage (BAL) [Baseline]

  3. Serum KL-6 [Baseline]

    Serum KL-6 is a known marker of alveolar epithelial damage in SSc-ILD

  4. Measurements of pepsin and pH in the Exhaled breath condensate (EBC) [12 months]

Secondary Outcome Measures

  1. Changes from baseline in longitudinal lung function assessment [Baseline, month 6, month 12, month 18]

    Spirometry with total lung capacity, diffusing capacity for CO

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients aged > 18 years

  • Diagnosis of SSc (American College of Rheumatology criteria)

  • Interstitial lung disease (>5% extent of ILD on HRCT)

  • Only for bronchoscopy: presence of troublesome cough and/or GER symptoms and/or recurrent chest infections and/or asymmetry of ILD changes on CT

Exclusion Criteria:
  • Significant communication difficulties

  • Unable to perform reliable lung function tests

  • Current smokers

  • Only for bronchoscopy: FEV1 less than 1L or DLCO less than 30% of the predicted

Contacts and Locations

Locations

Site City State Country Postal Code
1 Royal free hospital London United Kingdom NW3 2PF
2 Royal Brompton hospital London United Kingdom SW3 6NP

Sponsors and Collaborators

  • Royal Brompton & Harefield NHS Foundation Trust

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Royal Brompton & Harefield NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT02136394
Other Study ID Numbers:
  • 2013OE006B
First Posted:
May 13, 2014
Last Update Posted:
Apr 7, 2016
Last Verified:
Apr 1, 2016

Study Results

No Results Posted as of Apr 7, 2016